| Autor: |
Matrone, Antonio, Kroiss, Matthias, Gild, Matti L., Hamidi, Sarah, Sayehli, Cyrus Michael, Siddal, Rhonda, Gambale, Carla, Prete, Alessandro, Hu, Mimi I., Robinson, Bruce G., Elisei, Rossella |
| Předmět: |
|
| Zdroj: |
Thyroid; Sep2024, Vol. 34 Issue 9, p1177-1180, 4p |
| Abstrakt: |
This document is a letter to the editor of the journal Thyroid discussing the prevalence of erectile dysfunction (ED) in patients with RET-altered thyroid cancer who are treated with selpercatinib. The authors conducted a retrospective cohort study of 25 male patients and found that 92% of them reported ED. The study suggests that ED may be a common side effect of selpercatinib treatment and that phosphodiesterase-5 inhibitors (PDE-5i) may be effective in managing this adverse event. Further research is needed to confirm these findings and explore optimal management strategies. The authors acknowledge the support of Eli Lilly and Company in reviewing the study. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
